NRCME Drug Abuse and Alcoholism 6

Question 1

A 44-year-old commercial driver presents for a DOT physical with documentation from his addiction medicine specialist confirming 2 years of stable methadone maintenance therapy (MMT) for opioid use disorder, consistently negative urine drug screens (excluding methadone), and no behavioral concerns. He requests full certification. What is the correct FMCSA determination?

Accepted Answer

The driver is not medically qualified to operate a CMV while on methadone maintenance therapy

Answer

Under FMCSA guidelines, drivers using methadone — a Schedule II controlled substance — for opioid maintenance therapy are not medically qualified to operate CMVs, regardless of therapeutic stability, duration of sobriety, or specialist documentation. The agency's position is that adequate safety data does not exist to support certification of drivers on opioid maintenance therapy. Physician clearance letters do not override this disqualification. This same principle extends to buprenorphine-based maintenance therapies.

Question 2

Following a DOT random drug test positive for cocaine, a CMV driver completed the full SAP-prescribed rehabilitation program and received a written return-to-duty clearance letter from the Substance Abuse Professional. Which of the following must occur BEFORE the driver is permitted to resume any safety-sensitive duties?

Accepted Answer

The driver must produce a negative result on a directly observed return-to-duty DOT drug test

Answer

Per 49 CFR Part 40.305, after a SAP has evaluated the driver, recommended and verified completion of treatment or education, and issued a return-to-duty clearance, the driver still cannot resume safety-sensitive functions until they pass a directly observed return-to-duty drug test with a negative result. The MRO reviews lab results but does not independently authorize return to duty — that gate is the negative test itself. A supervised transitional work period and internal company knowledge tests have no basis in DOT regulations.

Question 3

A 50-year-old CMV driver's spouse reports he drinks 8–10 drinks nightly, has continued despite a physician warning about early liver fibrosis, has abandoned his hobbies, has been arrested twice for DUI, spends considerable time each morning recovering from the prior night, and craves alcohol throughout the day. At the exam, the driver denies any problems with alcohol. Based on DSM-5 criteria and available collateral information, what is his AUD severity classification?

Accepted Answer

Severe AUD (≥6 criteria met); collateral information is clinically valid for DSM-5 assessment

Answer

DSM-5 classifies AUD severity by the number of criteria met in a 12-month period: mild (2–3), moderate (4–5), severe (6–11). This driver meets at least 6 discrete criteria: (1) continued use despite physical harm (liver fibrosis warning), (2) neglect of major activities (hobbies abandoned), (3) continued use despite recurrent legal problems (DUI arrests), (4) significant time spent recovering, (5) craving, and (6) impaired control implied by persistent heavy use. DSM-5 explicitly permits collateral information from family or others as valid input for diagnosis — patient denial does not nullify clinically corroborated findings.

Question 4

During an NRCME physical, a CMV driver with a prior history of alcohol use disorder denies any alcohol use over the past 6 months. You suspect unreported relapse and order laboratory biomarker testing. Which of the following has the HIGHEST specificity for chronic heavy alcohol consumption over the preceding 2–4 weeks while minimizing false positives from non-alcoholic conditions?

Accepted Answer

Phosphatidylethanol (PEth)

Answer

Phosphatidylethanol (PEth) is a direct ethanol metabolite that forms exclusively in red blood cell membranes in the presence of ethanol — it cannot be produced by any other mechanism, yielding specificity exceeding 99%. Its detection window of 2–4 weeks reflects chronic heavy use. GGT and MCV are indirect markers frequently elevated by non-alcoholic causes (liver disease, medications, B12/folate deficiency, hypothyroidism). CDT has better specificity than GGT or MCV but is still inferior to PEth and can be affected by certain liver diseases or genetic variants. PEth is increasingly considered the gold standard for objective verification of heavy alcohol exposure.

Question 5

A CMV driver undergoing random DOT breath alcohol testing has a screening result of 0.026, followed by a confirmation result of 0.029. He has not yet operated a vehicle today. According to 49 CFR Parts 40 and 382, which of the following correctly describes all required consequences of this result?

Accepted Answer

The driver must be immediately removed from all safety-sensitive functions for a minimum of 8 hours; no SAP referral, return-to-duty test, or follow-up testing program is required for this result level

Answer

Under DOT regulations, a confirmed BAC of 0.02–0.039 constitutes an 'action level,' not a violation. At this level, the driver must be removed from all safety-sensitive functions immediately for a minimum of 8 hours — not until the next calendar day, and not until retested. Critically, this does NOT trigger violation consequences: no SAP referral, no return-to-duty test, and no follow-up testing program are required. Only a confirmed BAC of 0.04 or greater constitutes a rule violation requiring SAP evaluation, return-to-duty testing, and a follow-up testing program. Many examiners incorrectly conflate the two thresholds.

NRCME - National Registry of Certified Medical Examiners Practice Test

NRCME - National Registry of Certified Medical Examiners Practice Test

NRCME Drug Abuse and Alcoholism 6